Drug developer Savient Pharmaceuticals Inc. announced Tuesday it will sell the bulk of its assets to Crealta Pharmaceuticals LLC, which submitted a $120.4 million offer at the company's bankruptcy auction.
A New Jersey federal judge on Wednesday said that shareholders bringing a derivative action against the leadership of American Oriental Bioengineering Inc. can serve the company’s China-based officers and directors through their U.S.-based counsel.
This past year, Sullivan & Cromwell LLP's Frank Aquila guided Amgen Inc. in its $10.4 billion acquisition of Onyx Pharmaceuticals Inc., strengthening the biotechnology firm's cancer drug portfolio and earning him a spot among Law360's Life Sciences MVPs of 2013.
A plaintiff in multidistrict litigation over Procter & Gamble Manufacturing Co. dental cream told the 11th Circuit on Wednesday that a lower court had erred in excluding expert testimony linking the cream to her neurological damage.
The U.S. Food and Drug Administration advised manufacturers on Wednesday to stop indicating certain antibiotics for use as a growth aid in animal feed, citing the effects the practice can have on bacteria harmful to human health.
The Federal Trade Commission finalized the settlement of its antitrust case over Actavis Inc.'s $8.5 billion acquisition of Warner Chilcott PLC, after Actavis agreed to divest three oral contraceptives and an osteoporosis treatment to a New Jersey-based pharmaceuticals manufacturer, the FTC said Wednesday.
A Massachusetts judge granted class certification on Wednesday to a group of direct purchasers alleging AstraZeneca PLC and others breached antitrust laws by engineering the delay of a generic form of heartburn drug Nexium.
Federal and state judges on Wednesday told attorneys representing drugmakers and medical device firms about their biggest pet peeves in personal injury litigation, saying too many motions related to discovery and expert testimony were wastes of time and outlining in animated fashion their ideal ways of choosing bellwether suits.
Potential provisions in the Trans-Pacific Partnership on drug patent protections and the length of copyright terms came under fire recently, with Democratic lawmakers, library associations and consumer groups voicing concern over proposals that are currently on the table.
The Federal Circuit on Wednesday rebuffed St. Jude Medical Inc.'s bid to have the court reconsider its ruling that a St. Jude patent for a vascular closure device was not protected by the U.S. patent code's safe-harbor provision against allegations of double-patenting, and was therefore invalid.
The Federal Circuit on Wednesday reversed a district court’s decision in a patent infringement suit between Galderma Laboratories LP and Tolmar Inc., finding that the lower court erred in deciding that claims in four patents owned by Galderma and affiliates are not invalid as obvious.
A Michigan federal judge on Wednesday granted class certification to recipients of Stryker Corp. faxes promoting orthopedics seminars, advancing a Cincinnati medical practice’s claims that the device maker’s faxes violated the Telephone Consumer Protection Act by not including an opt-out notice.
Plaintiffs in a cluster of product liability lawsuits against a Johnson & Johnson unit over the antipsychotic drug Risperdal told a Pennsylvania judge on Tuesday that documents detailing the medication’s risks were too vital to the public interest to remain under seal as part of court proceedings.
Genetic testing company Invitae Corp. asked a Utah federal court Monday to throw out Myriad Genetics Inc.’s suit alleging Invitae infringed on its patents relating to genetic screening for breast cancer, saying the court lacks jurisdiction because Invitae has no contacts in Utah.
A personal injury boutique told a Texas appeals court Monday that a former associate's claim to millions in attorneys' fees from a settlement with GlaxoSmithKline LLC over its development and marketing of Avandia must be arbitrated even though his compensation agreement lacks such a requirement.
A New Jersey firm on Monday asked a federal judge to grant it summary judgment in its case against a former client who brought a whistleblower suit against Novartis AG alleging tax improprieties, saying the client refused to pay for services after failing to secure an award.
The Federal Trade Commission asked a Pennsylvania federal judge Monday to add Teva Pharmaceutical Industries Ltd. as a defendant in its antitrust suit over payments Provigil maker Cephalon Inc. made to block generic versions of its drug, citing Teva's acquisition of the company.
Princeton HealthCare System won access to a New Jersey county prosecutor’s files on Friday, in its effort to dodge a suit brought by the estate of a Princeton patient who died after being poisoned by his wife, an ex-employee of co-defendant Bristol-Myers Squibb Inc.
A California federal judge on Monday tossed a putative class action accusing dental products maker Align Technology Inc. and two of its executives of violating federal securities laws by failing to timely write down tens of millions of dollars of Align’s goodwill that was impaired.
A California federal judge preserved claims on Monday in the U.S. Securities and Exchange Commission's fraud suit against an ex-Hansen Medical Inc. executive, finding there was enough evidence showing he may have helped create phony sales of medical equipment that grossly inflated the company's revenues.
For the time being, patience and compliance are the only options for U.S. medicine and medical device manufacturers who require licenses to export their products to Iran. Waiting for an export license may be difficult, but the consequence of not having one can be a bitter pill to swallow, say attorneys at Reed Smith LLP.
No document review mechanism guarantees perfection, but the adoption of predictive coding has the potential to drastically alter the way in which documents are reviewed and produced in complex pharmaceutical and medical device litigation, says Jessica Sykora of Norton Rose Fulbright.
You might have heard this before — a cancer patient was treated with Aredia/Zometa, which, it is claimed, caused the patient to suffer from osteonecrosis of the jaw. A lawsuit is filed, the patient subsequently dies from the cancer, the plaintiff lawyers do not file the requisite paperwork to substitute in a new party, and the case is dismissed. But the defendant is not prejudiced by this kerfuffle, right? Wrong, says Stephen McConnell of Reed Smith LLP.
In light of the proposed e-discovery amendments to the Federal Rules of Civil Procedure, businesses need to set themselves up to efficiently respond to discovery and requests for information from their counsel by implementing and following document-control policies as part of normal business practices. The failure to do so will eventually consume vast amounts of employee time, say Steven Cvitanovic and Colin Murphy of Haight Brown & Bonesteel LLP.
While the technology at issue in Commil USA LLC v. Cisco Systems Inc. was not life sciences, the implications of the Federal Circuit's decision, and the trend in the law it reflects, likely will be significant for companies that often rely on method-of-treatment, mechanism-of-action and method-of-manufacturing patents as key value drivers. Such patents may be materially weakened, say Eric Marandett and Diana Huang of Choate Hall & Stewart LLP.
In Rowland v. Novartis Pharmaceuticals Corp., three Pennsylvania plaintiffs — merely because they were rousted to multidistrict litigation — received the advantage of the different choice-of-law rules for states to which they had no connection, rather than being bound by the choice-of-law rules of their actual domiciliary state. Where, as in Rowland, the plaintiff is a pure litigation tourist, this is an absurd result, says James Beck of Reed Smith LLP.
There are several unique defenses, depending on the state, available to defendant pharmaceutical companies which arise from the discord between consumer protection statutes and prescription drugs, say Yvonne McKenzie and Gabriel Vidoni at Pepper Hamilton LLP.
What is the thinking as to whether leaky air conditioner cases warrant multidistrict litigation treatment? On Dec. 5, the Judicial Panel on Multidistrict Litigation heads to Vegas to find out. This will bring a temperature shift in more ways than one from the September hearing, where the panel considered a potential MDL proceeding arising from allegedly defective clothes dryers, says Alan Rothman of Kaye Scholer LLP.
In addition to continued headline-grabbing litigation involving pharmaceutical companies in the wake of PLIVA Inc. v. Mensing, 2013 brought a number of important cases informing everything from class certification questions and product labeling trends to False Claims Act liability and fracking disputes, say attorneys at Weil Gotshal & Manges LLP.
China's Food and Drug Administration recently announced changes to its Drug Registration Rules, which, while demonstrating the agency’s determination to foster innovation, may not achieve a balance between multinational drug companies and domestic competitors in its current shape, says Katherine Wang of Ropes & Gray LLP.